Photo from wikipedia
Three biotherapies – etanercept, adalimumab and ustekinumab – are licensed in childhood psoriasis. The few data available on their efficacy and tolerance are mainly derived from industry trials. However, biological… Click to show full abstract
Three biotherapies – etanercept, adalimumab and ustekinumab – are licensed in childhood psoriasis. The few data available on their efficacy and tolerance are mainly derived from industry trials. However, biological drug survival impacts long‐term performance in real‐life settings.
Keywords:
psoriasis;
childhood psoriasis;
drug survival;
biological drug
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!